Cipher Pharmaceuticals (PHE) Ratios
Cipher Pharmaceuticals Ratios
DE:PHE's free cash flow for Q2 2026 was $2.96M. For the 2026 fiscal year, DE:PHE's free cash flow was decreased by $-15.52K and operating cash flow was $2.98M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.12 | 1.94 | 9.19 | 4.07 | 2.39 |
| Quick Ratio | 0.79 | 1.64 | 8.62 | 3.84 | 2.25 |
| Cash Ratio | 0.30 | 0.90 | 7.58 | 3.08 | 1.67 |
| Solvency Ratio | 1.16 | 0.26 | 3.92 | 2.85 | 0.66 |
| Operating Cash Flow Ratio | 1.21 | 0.98 | 3.05 | 1.13 | 1.12 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -2.21M | $ -21.68M | $ 42.76M | $ 28.46M | $ 16.57M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.25 | 0.00 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.04 | 0.40 | 0.00 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.04 | 0.28 | 0.00 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.04 | 0.28 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.24 | 1.59 | 1.07 | 1.15 | 1.33 |
| Debt Service Coverage Ratio | 29.05 | 0.00 | 0.00 | 0.00 | 112.59 |
| Interest Coverage Ratio | 14.17 | 0.00 | 0.00 | 0.00 | 128.49 |
| Debt to Market Cap | 0.02 | 0.16 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.26 | 1.64 | 0.01 | 0.02 | 0.02 |
| Net Debt to EBITDA | -0.08 | 1.92 | -3.42 | -2.36 | -1.47 |
| Profitability Margins | |||||
| Gross Profit Margin | 65.79% | 72.24% | 80.77% | 80.69% | 83.21% |
| EBIT Margin | 32.73% | 23.52% | 48.68% | 53.45% | 59.51% |
| EBITDA Margin | 46.94% | 35.56% | 54.48% | 58.23% | 62.25% |
| Operating Profit Margin | 32.73% | 23.52% | 54.48% | 58.23% | 53.87% |
| Pretax Profit Margin | 34.02% | 8.86% | 59.92% | 55.52% | 50.40% |
| Net Profit Margin | 54.17% | 34.60% | 96.32% | 128.83% | 35.36% |
| Continuous Operations Profit Margin | 54.17% | 34.60% | 96.32% | 128.83% | 35.36% |
| Net Income Per EBT | 159.23% | 390.69% | 160.74% | 232.04% | 70.15% |
| EBT Per EBIT | 103.94% | 37.65% | 109.99% | 95.35% | 93.55% |
| Return on Assets (ROA) | 17.80% | 7.10% | 23.69% | 36.10% | 15.02% |
| Return on Equity (ROE) | 22.07% | 11.28% | 25.31% | 41.57% | 19.94% |
| Return on Capital Employed (ROCE) | 12.80% | 5.50% | 14.27% | 18.69% | 30.04% |
| Return on Invested Capital (ROIC) | 12.78% | 5.49% | 14.26% | 18.66% | 21.04% |
| Return on Tangible Assets | 41.55% | 17.41% | 29.73% | 48.15% | 24.02% |
| Earnings Yield | 9.95% | 4.69% | 19.15% | 37.41% | 20.84% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.59 | 2.41 | 4.16 | 3.04 | 3.30 |
| Payables Turnover | 2.75 | 1.58 | 0.88 | 0.97 | 0.66 |
| Inventory Turnover | 2.15 | 1.60 | 1.36 | 1.86 | 2.23 |
| Fixed Asset Turnover | 90.38 | 49.06 | 52.64 | 42.98 | 43.80 |
| Asset Turnover | 0.33 | 0.21 | 0.25 | 0.28 | 0.42 |
| Working Capital Turnover Ratio | 4.75 | 1.08 | 0.59 | 0.90 | 1.61 |
| Cash Conversion Cycle | 116.85 | 148.44 | -60.88 | -58.67 | -276.15 |
| Days of Sales Outstanding | 79.53 | 151.63 | 87.76 | 120.08 | 110.75 |
| Days of Inventory Outstanding | 169.90 | 228.30 | 267.49 | 196.76 | 163.48 |
| Days of Payables Outstanding | 132.58 | 231.50 | 416.13 | 375.51 | 550.37 |
| Operating Cycle | 249.43 | 379.93 | 355.25 | 316.85 | 274.23 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.19 | 0.79 | 0.63 | 0.42 | 0.52 |
| Free Cash Flow Per Share | 1.19 | 0.79 | 0.63 | 0.42 | 0.52 |
| Dividend Paid and CapEx Coverage Ratio | 1061.80 | 444.23 | 111.10 | 130.56 | 0.00 |
| Capital Expenditure Coverage Ratio | 1061.80 | 444.23 | 111.10 | 130.56 | 0.00 |
| Operating Cash Flow Coverage Ratio | 5.50 | 0.48 | 45.32 | 24.71 | 26.77 |
| Operating Cash Flow to Sales Ratio | 0.59 | 0.59 | 0.76 | 0.51 | 0.63 |
| Free Cash Flow Yield | 10.81% | 7.93% | 15.01% | 14.74% | 37.11% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 10.06 | 21.31 | 5.22 | 2.67 | 4.80 |
| Price-to-Sales (P/S) Ratio | 5.44 | 7.37 | 5.03 | 3.44 | 1.70 |
| Price-to-Book (P/B) Ratio | 2.22 | 2.40 | 1.32 | 1.11 | 0.96 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 9.25 | 12.61 | 6.66 | 6.78 | 2.69 |
| Price-to-Operating Cash Flow Ratio | 9.24 | 12.59 | 6.65 | 6.73 | 2.69 |
| Price-to-Earnings Growth (PEG) Ratio | 0.08 | -0.52 | -0.21 | 0.01 | 0.07 |
| Enterprise Value Multiple | 11.52 | 22.65 | 5.81 | 3.55 | 1.26 |
| Enterprise Value | 277.49M | 268.74M | 66.94M | 42.79M | 17.19M |
| EV to EBITDA | 11.52 | 22.65 | 5.81 | 3.55 | 1.26 |
| EV to Sales | 5.41 | 8.05 | 3.16 | 2.07 | 0.78 |
| EV to Free Cash Flow | 9.18 | 13.78 | 4.19 | 4.08 | 1.24 |
| EV to Operating Cash Flow | 9.17 | 13.75 | 4.18 | 4.05 | 1.24 |
| Tangible Book Value Per Share | 1.44 | 0.25 | 2.47 | 1.82 | 0.73 |
| Shareholders’ Equity Per Share | 4.94 | 4.14 | 3.16 | 2.55 | 1.46 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.59 | -2.91 | -0.61 | -1.32 | 0.30 |
| Revenue Per Share | 2.01 | 1.35 | 0.83 | 0.82 | 0.82 |
| Net Income Per Share | 1.09 | 0.47 | 0.80 | 1.06 | 0.29 |
| Tax Burden | 1.59 | 3.91 | 1.61 | 2.32 | 0.70 |
| Interest Burden | 1.04 | 0.38 | 1.23 | 1.04 | 0.85 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| SG&A to Revenue | 0.32 | 0.37 | 0.22 | 0.19 | 0.00 |
| Stock-Based Compensation to Revenue | 0.03 | 0.03 | 0.06 | 0.02 | 0.01 |
| Income Quality | 1.11 | 1.69 | 0.78 | 0.40 | 1.78 |
Currency in USD